Modality
Fusion Protein
MOA
STINGag
Target
AHR
Pathway
Amyloid
ADPKDGA
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
~May 2020
→ ~Aug 2021
Phase 2
Nov 2021
→ Apr 2028
Phase 2Current
NCT04327823
2,806 pts·ADPKD
2023-10→2028-04·Not yet recruiting
NCT04260996
2,989 pts·ADPKD
2021-11→TBD·Completed
5,795 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-162.0y awayPh2 Data· ADPKD
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2
Complet…
P2
Not yet…
Catalysts
Ph2 Data
2028-04-16 · 2.0y away
ADPKD
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04327823 | Phase 2 | ADPKD | Not yet recr... | 2806 | EDSS |
| NCT04260996 | Phase 2 | ADPKD | Completed | 2989 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| RHH-5389 | Roche | Preclinical | RET | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |